|
|||
|
Home > About Xigen : History and Mission | ||
|
|||
|
|
|
|
History and Mission
Xigen SA is a private Swiss biopharmaceutical company founded in 2002 as a spin-off from the University Hospital of Lausanne (CHUV) in Switzerland. Dr. Christophe Bonny, CEO and co-founder, is a renowned molecular biologist with over a decade’s research expertise on intracellular peptides and signalling.
Xigen is developing innovative therapeutic peptides for underserved medical needs in the area of inflammation. Xigen’s technology platform enables the design and synthesis of cell-penetrating peptides with enhanced metabolic stability, using proprietary carrier motifs to selectively deliver them to their intracellular targets. The technology also has the potential to produce therapeutics in the fields of CNS, oncology and virology. The technology can be applied to a range of therapeutic molecules to improve their efficacy.
Xigen obtained CHF 26 million in a Series A financing round in 2005, and a further CHF 20 million from its principal investor, Tilocor Life Science, in a Series B round completed in 2009. Xigen is actively seeking industry partners for the development of several promising compounds in its growing pipeline. The company currently has 20 employees.
Xigen is developing innovative therapeutic peptides for underserved medical needs in the area of inflammation. Xigen’s technology platform enables the design and synthesis of cell-penetrating peptides with enhanced metabolic stability, using proprietary carrier motifs to selectively deliver them to their intracellular targets. The technology also has the potential to produce therapeutics in the fields of CNS, oncology and virology. The technology can be applied to a range of therapeutic molecules to improve their efficacy.
Xigen obtained CHF 26 million in a Series A financing round in 2005, and a further CHF 20 million from its principal investor, Tilocor Life Science, in a Series B round completed in 2009. Xigen is actively seeking industry partners for the development of several promising compounds in its growing pipeline. The company currently has 20 employees.
